Answers are grounded in this paper and cite their sources.
To The Editors: In our recently published review1 of the acellular vaccine efficacy trials, the results of one trial, called Stockholm 3, were omitted because they were then unavailable. On May 16 Dr. Patrick Olin and his colleagues presented those results at a public meeting. This letter is written as an addendum to our review and to complete the story. The Stockholm 3 trial compared the three-component (pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin) vaccine manufactured by Biocine and the five-component (PT, FHA, pertactin, agglutinogen 2 and agglutinogen 3) vaccine manufactured by Connaught Laboratories Ltd. (CLL, now Pasteur Mérieux Connaught-Canada) with the whole cell vaccine manufactured by Medeva-Wellcome that is routinely used in the United Kingdom. Each vaccine was given to >18 000 children at 3, 5 and 12 months of age. The Stockholm 3 trial is not strictly comparable to Stockholm 2 as it was done under passive rather than active surveillance, using a different immunization schedule and a slightly modified case definition (culture was the only confirmation criterion). However, it is worth noting as a reference that the absolute efficacy of the same five-component vaccine in Stockholm 2 against pertussis by the strict WHO definition and against all pertussis, respectively, was 85% and 78%. Because there was no unvaccinated control arm in Stockholm 3, the analysis focused on relative efficacy, with the whole cell vaccine assigned a relative risk of 1. For culture-positive pertussis accompanied by 21 days or more of paroxysmal cough (close to but not identical with the WHO clinical definition of typical pertussis that has been used to compare results between vaccines and between trials), the three- and five-component acellular vaccines gave relative risks (and confidence limits) of 1.38 (0.71 to 2.69) and 0.85 (0.41 to 1.79), respectively. Thus they could not be distinguished statistically from the whole cell vaccine. A second case definition was positive pertussis culture with cough of any duration, encompassing both mild and typical pertussis. By this definition the relative risks of the three- and five-component vaccines were 2.55 (1.50 to 4.33) and 1.40 (0.78 to 2.52), respectively. The three-component vaccine was distinctly less efficacious than the five-component or whole cell vaccine, which were indistinguishable. Inasmuch as the Biocine 3 vaccine contained PT, FHA and pertactin but no agglutinogens, the results suggest that the agglutinogens were the components responsible for the difference between the five- and three-component vaccine in efficacy against mild disease, although differences in the quantities of other components such as the PT may have played a role. Another whole cell vaccine was demonstrated to be highly efficacious against both severe and mild pertussis, confirming that the efficacy of immunogenic whole cell vaccines is not easy to match. Our impression remains, as stated in our review, that PT is the principal protective factor against typical severe pertussis and that the addition of attachment factors to PT may be most useful for the prevention of mild disease or colonization. In this regard the agglutinogens may be important. The five components in the CLL vaccine apparently reconstituted an efficacious whole cell vaccine, with less reactogenicity. Stanley A. Plotkin, M.D. Michel Cadoz, M.D. Pasteur Mérieux Connaught; Marnes-la-Coquette, France
No takes yet. Share an insight, caveat, or question.
Plotkin et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: